1-4 of 4
Mario Sznol
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Free
Adi Diab, Nizar M. Tannir, Salah-Eddine Bentebibel, Patrick Hwu, Vassiliki Papadimitrakopoulou, Cara Haymaker, Harriet M. Kluger, Scott N. Gettinger, Mario Sznol, Scott S. Tykodi, Brendan D. Curti, Mary A. Tagliaferri, Jonathan Zalevsky, Alison L. Hannah, Ute Hoch, Sandra Aung, Christie Fanton, Ahsan Rizwan, Ernesto Iacucci, Yijie Liao, Chantale Bernatchez, Michael E. Hurwitz, Daniel C. Cho
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2020) 10 (8): 1158–1173.
https://doi.org/10.1158/2159-8290.CD-19-1510
Published: 03 August 2020
View articletitled, Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Open the PDF for Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02) in another window
Includes: Supplementary data
Journal Articles

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

Free
Lawrence Fong, Andrew Hotson, John D. Powderly, Mario Sznol, Rebecca S. Heist, Toni K. Choueiri, Saby George, Brett G.M. Hughes, Matthew D. Hellmann, Dale R. Shepard, Brian I. Rini, Shivaani Kummar, Amy M. Weise, Matthew J. Riese, Ben Markman, Leisha A. Emens, Daruka Mahadevan, Jason J. Luke, Ginna Laport, Joshua D. Brody, Leonel Hernandez-Aya, Philip Bonomi, Jonathan W. Goldman, Lyudmyla Berim, Daniel J. Renouf, Rachel A. Goodwin, Brian Munneke, Po Y. Ho, Jessica Hsieh, Ian McCaffery, Long Kwei, Stephen B. Willingham, Richard A. Miller
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2020) 10 (1): 40–53.
https://doi.org/10.1158/2159-8290.CD-19-0980
Published: 09 January 2020
View articletitled, Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Open the PDF for Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer in another window
Includes: Supplementary data
Journal Articles

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

Free
Salah-Eddine Bentebibel, Michael E. Hurwitz, Chantale Bernatchez, Cara Haymaker, Courtney W. Hudgens, Harriet M. Kluger, Michael T. Tetzlaff, Mary A. Tagliaferri, Jonathan Zalevsky, Ute Hoch, Christie Fanton, Sandra Aung, Patrick Hwu, Brendan D. Curti, Nizar M. Tannir, Mario Sznol, Adi Diab
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2019) 9 (6): 711–721.
https://doi.org/10.1158/2159-8290.CD-18-1495
Published: 03 June 2019
View articletitled, A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
Open the PDF for A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors in another window
Includes: Supplementary data
Journal Articles

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Free
Ryan J. Sullivan, Jeffrey R. Infante, Filip Janku, Deborah Jean Lee Wong, Jeffrey A. Sosman, Vicki Keedy, Manish R. Patel, Geoffrey I. Shapiro, James W. Mier, Anthony W. Tolcher, Andrea Wang-Gillam, Mario Sznol, Keith Flaherty, Elizabeth Buchbinder, Richard D. Carvajal, Anna M. Varghese, Mario E. Lacouture, Antoni Ribas, Sapna P. Patel, Gary A. DeCrescenzo, Caroline M. Emery, Anna L. Groover, Saurabh Saha, Mary Varterasian, Dean J. Welsch, David M. Hyman, Bob T. Li
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (2): 184–195.
https://doi.org/10.1158/2159-8290.CD-17-1119
Published: 04 February 2018
View articletitled, First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Open the PDF for First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study in another window
Includes: Supplementary data